Judith Ng-Cashin, M.D., joined Novotech in 2023 as its Chief Medical Officer. With a rich background encompassing over two decades in the international pharmaceutical, biotech, and CRO sectors, Dr. Ng-Cashin plays a pivotal role in shaping Novotech's global multi-regional later-phase strategy and ensuring the highest quality delivery of services to both sponsors and patients. Before her role at Novotech, she held key senior executive positions, including CMO and CSO roles at organizations such as Eagle Pharmaceuticals, Inc., Syneos Health, AoBiome Therapeutics, and INC Research. Dr. Ng-Cashin also serves as a valued member of the Scientific Advisory Board for Revibe Technologies, and most recently sat on the Board of Directors for DIA, and contributes as an Affiliate Mentor for Duke New Ventures within Duke University's Office for Translation and Commercialization. Dr. Ng-Cashin's commitment to advancing healthcare innovation is underscored by her impressive track record of successful clinical trials and her dedication to improving patient outcomes. Her educational background includes an MD from Rush Medical School, residency training at The University of Chicago Pritzker School of Medicine, and fellowships in infectious diseases and hematology/oncology from the University of North Carolina at Chapel Hill. She holds a dual BA/BS degree in Mathematics and Psychology, further enriching her multidisciplinary approach to healthcare leadership.